Medicines & supplements – Current GIS Alerts 2026
Found 734 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Carmustine Accord
The solvent component of the medicine does not meet quality requirements due to a negative test result for the "residue on evaporation" parameter, with a value several times above the acceptable limit. Potential effects: poisoning, toxic effects, complications after intravenous administration.
Egoropal
A routine FDA inspection revealed serious deficiencies in aseptic manufacturing processes; the assessed risk to product quality and patient safety for aseptically filled batches on the market is high. The product is a parenteral solution for injection. Potential effects: infections after parenteral administration, severe complications, lack of treatment safety.
Egoropal
A routine FDA inspection revealed serious deficiencies in aseptic manufacturing processes. The risk assessment indicated a high risk to product quality and patient safety for aseptically filled batches available on the market. Potential effects: infection, sepsis, serious complications, lack of treatment efficacy.
Palifren Long
An FDA inspection at the manufacturer revealed non-compliance in sterile/aseptic processing and procedures, indicating a threat to the quality of these medicinal products and forming the basis for their withdrawal from the market. Potential effects: infection, poisoning, severe complications after injection.
Palifren Long
The inspection revealed non-compliances in sterile/aseptic processing and procedures, indicating a risk to the quality of the medicinal products. Potential effects: infection, sepsis, loss of sterility of a parenterally administered product.
Palifren Long
An FDA inspection at the manufacturer found non-compliances in sterile/aseptic processing and procedures. Deviations in sterile manufacturing were detected, posing a risk to the quality of these medicinal products. Potential effects: infection after injection, poisoning, severe systemic complications.
Palifren Long
An FDA inspection at the manufacturer revealed non-compliances in sterile/aseptic processing and procedures, posing a risk to the quality and sterility of Palifren Long prolonged-release injectable suspension products. Potential effects: infection after injection, severe systemic complications, lack of treatment safety.
Clarithromycin Adamed
Falsification of the active substance Clarithromycin and lack of confirmation that quality requirements for the key component of this parenteral product (solution for infusion) are met have been identified, so a risk to patients' health or life cannot be excluded. Potential effects: lack of treatment efficacy, unpredictable adverse reactions, severe life-threatening complications.
Clarithromycin hameln
Lack of confirmed quality of the active substance used for batch 25D052 and non-compliance with GMP requirements in the supply chain. The product is a solution for infusion, so potential quality deviations carry an increased risk to patients' health and life. Potential effects: poisoning, lack of efficacy, complications during intravenous therapy.
Lorafen
An out-of-specification result was found in long-term stability testing (parameter: active substance release below the lower acceptance limit), which constitutes a real and direct threat to patients' health or life. Potential effects: reduced treatment efficacy, disease exacerbation, complications endangering health or life.
Itami
The identified quality defect is insufficient adhesion of the patch to the skin; the patch does not remain firmly attached, preventing the product from fulfilling its intended therapeutic function. Potencjalne skutki: lack of treatment efficacy, possible recurrence or worsening of symptoms.
PHELINUN
The identified discrepancy in the incorrectly described label on the vial with powder may pose a risk of incorrect preparation of the medicine, and thus a health risk to patients cannot be excluded. Potencjalne skutki: lack of treatment efficacy or complications related to an inappropriate dose of cytostatic drug.
Vitamina C Synteza
Brown spots were found on the capsules, which means non-compliance with quality requirements for the external appearance parameter; the authority decided that a risk to patients’ health cannot be excluded. Potential effects: potentially reduced medicine quality, lack of efficacy or unforeseen reactions.
Varilrix, Live varicella vaccine, Powder and solvent for solution for injection, not less than 10^3.3 PFU of varicella virus, Oka strain/0.5 ml; 1 dose (0.5 ml)
The reported signal concerned the occurrence of a serious adverse reaction related to the medicinal product and was assessed by the Pharmacovigilance Risk Assessment Committee (PRAC) at the European Medicines Agency (EMA). Potential effects: serious adverse reactions, post-vaccination complications.
BIOFLEKS 0.9% Isotonic Sodium Chloride Sterile, Natrii chloridum, 9 mg/ml, solution for infusion
Initially, the presence of liquid between the primary container and the outer foil was observed, raising suspicion of a quality defect; however, NIL testing confirmed that the product complies with requirements and poses no risk to patients. Potential effects: no identified health risk.
Xaloptic Combi
Increased solution osmolality and water loss leading to reduced volume may destabilize the tear film and cause ocular discomfort, irritation, burning, subjective visual disturbances, and worsening of dry eye symptoms, especially with long-term use of the product. Potential effects: eye irritation and discomfort, worsening dryness, possible transient visual disturbances.
Fibre 350 g
The presence of Salmonella spp. rods was found in one of five samples of the Fibre 350 g dietary supplement from the specified batch, indicating microbiological contamination and a possibility of foodborne infection after consumption. Potential effects: food poisoning, gastrointestinal ailments.
POLIPARIN 25000 IU/5 ml, Heparin sodium, solution for injection and infusion, 25000 IU/5 ml, 5 ml x 1 vial
Reported non‑conformities included “ganglionic thrombosis after administration of the product in several patients”. SMZ analysis confirmed public health hazards and the serious nature of adverse reactions, posing a real risk to patients. Potential effects: thrombosis, vascular complications, risk to health and life.
Vendal retard
The level of some related substances (a single unknown impurity and morphinone) exceeded the acceptable limit, which may affect the effectiveness and safety of the medicine and pose a real risk to human health. Potential effects: altered drug effect, adverse reactions, health risk.
Storvas CRT
It was found that the product does not meet quality requirements: result below the lower specification limit for the dissolution parameter, creating a real risk to patients’ health due to possible lack of efficacy. Potential effects: lack of treatment effectiveness, disease progression, cardiovascular complications.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.